Extended Data Fig. 9: Effects of CAR T-cell therapy on additional autoantibody responses.
From: CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial

Graphs show baseline (grey circles) and 6-months follow-up (blue circles) of autoantibody levels against various autoantigens in individual patients. CENP, centromere protein; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; NOR90, nucleolus organizing regions 90; NPX2, nuclear matrix protein 2; PM-SCL, polymyositis-systemic sclerosis.